HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers

Clinical Infectious Diseases

Volumn 52, Issue 5, 2011, Pages 681-687

  Hunt, Peter W ^a   Hatano, Hiroyu ^a   Sinclair, Elizabeth ^a   Lee, Tzong Hae ^b   Busch, Michael P ^a,b   Martin, Jeffrey N ^a   Mccune, Joseph M ^a   Deeks, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; HLA B57 ANTIGEN; HLA DR ANTIGEN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIREMIA;

ADULT; ANTIGENS, CD38; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 79951837963     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq202     Document Type: Article

References (43)

1. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-9. (Pubitemid 43882629)
2. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8 (+) T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008;29:1009-21.
3. + T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007;81:13904-15. (Pubitemid 350247883)
4. + elite suppressors. J Virol 2009;83:88-97.
5. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005;79:14169-78. (Pubitemid 41552715)
6. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004;103:966-72. (Pubitemid 38129558)
7. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007;104:6776-81. (Pubitemid 47175577)
8. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008;197:563-71. (Pubitemid 351321534)
9. Emu B, Sinclair E, Hatano H, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for longterm virus control. J Virol 2008;82:5398-407. (Pubitemid 351705247)
10. van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, van't Wout AB, Schuitemaker H. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009;23:19-28.
11. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-7. (Pubitemid 47301321)
12. *57 alleles. LoS One 2008;3: e3636.
13. Limou S, Le Clerc S, Coulonges C, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009;199:419-26.
14. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
15. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23:1059-67.
16. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4 (+) T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197:126-33. (Pubitemid 351263476)
17. Garbuglia AR, Salvi R, Di Caro A, et al. Peripheral lymphocytes of clinically non-progressor patients harbor inactive and uninducible HIV proviruses. J Med Virol 1995;46:116-21.
18. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005;41:1053-6. (Pubitemid 41368233)
19. Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent lowlevel viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009;83:329-35.
20. + T cells. Nature 2002;417:95-8. (Pubitemid 34498823)
21. Carbone J, Gil J, Benito JM, et al. Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug users. AIDS 2000;14:2823-9. (Pubitemid 32042745)
22. + T cell gains in human immunodeficiency virusinfected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534-43. (Pubitemid 36578959)
23. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004;351:760-8.
24. Busch MP, Glynn SA, Wright DJ, et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005;45:1853-63. (Pubitemid 43971412)
25. Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008;47:1446-52. (Pubitemid 351702728)
26. Lee TH, el-Amad Z, Reis M, et al. Absence of HIV-1 DNA in high-risk seronegative individuals using high-input polymerase chain reaction. AIDS 1991;5:1201-7.
27. Lee TH, Paglieroni T, Utter GH, et al. High-level long-term white blood cell microchimerism after transfusion of leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion 2005;45:1280-90. (Pubitemid 41647791)
28. Davidson R, MacKinnon J. Estimation and inference in econometrics. New York: Oxford University Press, 1993.
29. Julg B, Pereyra F, Buzon MJ, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4 (+) T cells in HIV elite controllers. Clin Infect Dis Jul. 2010;51:233-8.
30. Lassen KG, Lobritz MA, Bailey JR, et al. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 2009;5: e1000377.
31. *5801 HIV-1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong Ctl recognition. J Virol 2009;83:2743-55.
32. Lamine A, Caumont-Sarcos A, Chaix ML, et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 2007;21:1043-5. (Pubitemid 46684337)
33. Bailey JR, O'Connell K, Yang HC, et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 2008;82:7395-410. (Pubitemid 352031208)
34. Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007;81:2508-18.
35. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007;39:733-40. (Pubitemid 46848586)
36. Autran B, Murphy RL, Costagliola D, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008;22:1313-22.
37. Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis Sep. 202:705-16.
38. + T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol 2005;175:6117-22. (Pubitemid 41508099)
39. Begaud E, Chartier L, Marechal V, et al. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 2006;3:35.
40. Jennes W, Evertse D, Borget MY, et al. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol 2006;143:435-44.
41. Salkowitz JR, Purvis SF, Meyerson H, et al. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001;98:200-11.
42. Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4 (+) CD25 (+) FOXP3 (+) regulatory T cells. J Infect Dis 2009;199:1318-22.
43. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009;458:1034-8.